NEU
Neuren Pharmaceuticals Ltd
Pharmaceuticals
·
Healthcare
10
comments
6
fund managers
past 90 days
About Neuren Pharmaceuticals Ltd
Neuren Pharmaceuticals Ltd., founded in 2001 and headquartered in Camberwell, Australia, develops therapies for early-childhood neurodevelopmental disorders. The company operates through two segments: Commercial Products, which generates revenue from intellectual property licenses, royalties, and milestones; and Research and Development, focused on advancing clinical treatments for neurodevelopmental conditions. Neuren focuses on translating research into therapeutic solutions for neurological health.
Commentary Volume
10
Comments
6
Fund managers
0
Past 90 days
SOURCE
ACTION
COMMENT PREVIEW
FUND MANAGER
DATE
Loading...
.
​Loading...
Loading...
Loading...
Loading...
Source: Ipsum Capital Q4 Quarterly Letter · Published 14 March 2025
Report a problem
Loading...
.
Loading...
Loading...
Loading...
Loading...
§ Important Notice
The entries below are records originating from third-party statements. Thesis Tracker does not rank, recommend or endorse any fund manager, fund or security. Investment decisions should be made on the basis of the relevant Product Disclosure Statement and, where appropriate, advice from a licensed adviser.
Commentary
Sector
Healthcare
Market cap
$2B
Fund managers
6 managers
First covered
31 Dec 2023
Last updated
31 July 2025
Company Details
Related Themes
ic
Ipsum Capital
6 comments
ic
Amet Funds
4 comments
ic
Dolor
3 comments
Top Investors Covering MIN
§ Reminder
The entries above are records originating from third-party statements. Thesis Tracker does not rank, recommend or endorse any fund manager, fund or security. Investment decisions should be made on the basis of the relevant Product Disclosure Statement and, where appropriate, advice from a licensed adviser.
Frequently asked questions about Neuren Pharmaceuticals Ltd (ASX:NEU)
Frequently asked questions
Who is investing in Neuren Pharmaceuticals Ltd (ASX:NEU)?
Fund managers including Endeavor Asset Management, Milford Asset Management, Spheria Asset Management, Blackwattle Investment Partners, Oracle Advisory Group and Seneca Financial Solutions have invested in Neuren Pharmaceuticals Ltd (ASX:NEU).
What is the short interest in Neuren Pharmaceuticals Ltd (ASX:NEU)?
The short interest in Neuren Pharmaceuticals Ltd (ASX:NEU) is 5.72% which makes it the 34th most shorted stock on the ASX. Of the 126.6M shares that Neuren Pharmaceuticals Ltd has on issue, 7.2M have been sold short.
What does Neuren Pharmaceuticals Ltd (ASX:NEU) do?
Neuren Pharmaceuticals Ltd., founded in 2001 and headquartered in Camberwell, Australia, develops therapies for early-childhood neurodevelopmental disorders. The company operates through two segments: Commercial Products, which generates revenue from intellectual property licenses, royalties, and milestones; and Research and Development, focused on advancing clinical treatments for neurodevelopmental conditions. Neuren focuses on translating research into therapeutic solutions for neurological health.
Loading...